Cargando…

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND

BACKGROUND: The REWIND trial demonstrated cardiovascular (CV) benefits to patients with type 2 diabetes and multiple CV risk factors or established CV disease. This exploratory analysis evaluated the degree to which the effect of dulaglutide on CV risk factors could statistically account for its eff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Konig, Manige, Riddle, Matthew C., Colhoun, Helen M., Branch, Kelley R., Atisso, Charles M., Lakshmanan, Mark C., Mody, Reema, Raha, Sohini, Gerstein, Hertzel C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466679/ https://www.ncbi.nlm.nih.gov/pubmed/34563178 http://dx.doi.org/10.1186/s12933-021-01386-4

Ejemplares similares

Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial
por: Riddle, Matthew C, et al.
Publicado: (2021)

OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind
por: Konig, Manige, et al.
Publicado: (2020)

HbA(1c) Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial
por: Kwan, Anita Y.M., et al.
Publicado: (2022)

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
por: Dagenais, Gilles R., et al.
Publicado: (2020)

Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial
por: Franek, Edward, et al.
Publicado: (2022)

General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trial
por: Franek, Edward, et al.
Publicado: (2023)

Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study
por: Torre, Enrico, et al.
Publicado: (2020)

Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6‐month follow‐up from US real‐world data
por: Mody, Reema, et al.
Publicado: (2020)

Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review
por: Robinson, Susan, et al.
Publicado: (2020)

Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events
por: Ferdinand, Keith C., et al.
Publicado: (2016)

Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
por: Van, Joanna, et al.
Publicado: (2021)

Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial
por: Frias, Juan P., et al.
Publicado: (2021)

RP rewind
Publicado: (2020)

Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States
por: Boye, Kristina S., et al.
Publicado: (2019)

REWIND Diabetes for Octogenarians
por: Geberhiwot, Tarekegn
Publicado: (2021)

Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis
por: Patel, Hiren, et al.
Publicado: (2019)

Response to Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. Diabetes Care 2013;36:2915–2922
por: Riddle, Matthew C., et al.
Publicado: (2013)

Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study
por: Boye, Kristina, et al.
Publicado: (2020)

Unwinding and Rewinding: Double Faces of Helicase?
por: Wu, Yuliang
Publicado: (2012)

Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study
por: Nair, Radhika, et al.
Publicado: (2022)

Rewinding the waves: tracking underwater signals to their source
por: Kadri, Usama, et al.
Publicado: (2017)

Mistreatment in Residency: Intervening With the REWIND Communication Tool
por: Pang, Joyce, et al.
Publicado: (2022)

FRI638 Glycemic And Cost Outcomes In Hispanic/Latino People With Type 2 Diabetes Initiating Dulaglutide Or Basal Insulin In The US
por: Hoog, Meredith, et al.
Publicado: (2023)

Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11
por: Frias, Juan Pablo, et al.
Publicado: (2021)

Are U‐shaped relationships between risk factors and outcomes artifactual?
por: Shah, Reema, et al.
Publicado: (2022)

Levorphanol: Rewinding an Old, Bygone Multimodal Opioid Analgesic!
por: Nair, Abhijit S, et al.
Publicado: (2019)

The reconsolidation using rewind study (RETURN): trial protocol
por: Astill Wright, Laurence, et al.
Publicado: (2021)

Relationship Between A1C and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes: An analysis of baseline data from the ORIGIN trial
por: Ramachandran, Ambady, et al.
Publicado: (2012)

27 September 2013: Fast forward and rewind to our Origins
por: Antonella Del Rosso
Publicado: (2013)

A model‐based simulation of glycaemic control and body weight when switching from semaglutide to 3.0‐ and 4.5‐mg doses of once‐weekly dulaglutide
por: Tham, Lai San, et al.
Publicado: (2021)

Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial
por: Tuttolomondo, Antonino, et al.
Publicado: (2021)

Influence of the Strap Rewind Height During a Conical Pulley Exercise
por: Sabido, Rafael, et al.
Publicado: (2020)

Homecoming: rewinding the reductive evolution of the chloroplast genome for increasing crop yields
por: Llorente, Briardo, et al.
Publicado: (2021)

Cardiovascular outcomes trials with glucagon‐like peptide‐1 receptor agonists: A comparison of study designs, populations and results
por: Pantalone, Kevin M., et al.
Publicado: (2020)

Accurate Identification and Analysis of Human mRNA Isoforms Using Deep Long Read Sequencing
por: Tilgner, Hagen, et al.
Publicado: (2013)

Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11
por: Frias, Juan P., et al.
Publicado: (2021)

Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study
por: Mody, Reema, et al.
Publicado: (2019)

Rash, disseminated intravascular coagulation and legionella: Episode 10 and a rewind into the past
por: Thalanayar, Prashanth M., et al.
Publicado: (2015)

Rewinding the Molecular Clock: Looking at Pioneering Molecular Phylogenetics Experiments in the Light of Proteomics
por: Neely, Benjamin A., et al.
Publicado: (2021)

Cognitive function in adolescence and the risk for premature diabetes and cardiovascular mortality in adulthood
por: Twig, Gilad, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_alj71ijg9s407uf9dam1s9on7u